Abstract
We describe bedside-to-bench immunological and genetic elucidation of defective pyroptosis attributable to novel caspase 4 defect mediating pathogen-triggered inflammatory programmed cell death, in the setting of severe pneumonia and abscess-forming melioidosis in an overtly healthy host failing to clear Burkholderia pseudomallei infection, and how targeted adjunctive biological therapy led to a successful outcome.
Original language | English |
---|---|
Pages (from-to) | 94-97 |
Number of pages | 4 |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
Volume | 78 |
Issue number | 1 |
Early online date | 20 Sept 2023 |
DOIs | |
Publication status | Published - 15 Jan 2024 |
Bibliographical note
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].Keywords
- Humans
- Melioidosis/drug therapy
- Burkholderia pseudomallei/genetics
- Interferon-gamma/genetics
- Extracorporeal Membrane Oxygenation
- Mutation